Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – N-c doai
Patent
1997-05-08
1998-08-25
Geist, Gary
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
N-c doai
562623, 560251, 560187, 560106, A01N 4728, C07C 6702, C07C 6966, C07C 6976
Patent
active
057983836
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
This invention relates to novel aryloxycycloalkenyl- and aryloxyimino-cycloalkenylhydroxyurea compounds. The compounds of the present invention inhibit the action of 5-lipoxygenase enzyme and are useful in the prevention, treatment or alleviation of inflammatory diseases such as inflammatory bowel disease and rheumatoid arthritis, allergy and cardiovascular diseases in a mammalian subject, e.g., human subject. This invention also relates to pharmaceutical compositions comprising these compounds.
BACKGROUND ART
Arachidonic acid is known to be the biological precursor of several groups of endogenous metabolites, prostaglandins including prostacyclins, thromboxanes and leukotrienes. The first step of the arachidonic acid metabolism is the release of arachidonic acid and related unsaturated fatty acids from membrane phospholipids, via the action of phospholipase A.sub.2. Free fatty acids are then metabolized either by cyclooxygenase to produce the prostaglandins and thromboxanes or by lipoxygenase to generate hydroperoxy fatty acids which may be further metabolized to the leukotrienes. Leukotrienes have been implicated in the pathophysiology of inflammatory diseases, including rheumatoid arthritis, gout, asthma, ischemia reperfusion injury, psoriasis and inflammatory bowel diseases. Any drug that inhibits lipoxygenase is expected to provide significant new therapy for both acute and chronic inflammatory conditions.
For a review article on 5-lipoxygenase inhibitors, see H. Masamune and L. S. Melvin, Sr., Annual Reports in Medicinal Chemistry, 24 (1989) pp71-80 (Academic Press). More recently, further examples of 5-lipoxygenase inhibitors have been disclosed in International Patent Publication Nos. WO 94/14762 and WO 92/9566.
BRIEF DISCLOSURE OF THE INVENTION
The invention provides a compound of formula (I): ##STR2## wherein Ar is selected from the group consisting of: three substituents selected from alkoxy, C.sub.1-4 haloalkoxy, C.sub.2-4 alkoxyalkoxy, C.sub.1-4 alkylthio, hydroxy, halo, cyano, amino, C.sub.1-4 alkylamino, di (C.sub.2-8) alkylamino, C.sub.2-6 alkanoylamino, carboxy, C.sub.2-6 alkoxycarbonyl, phenyl optionally substituted with one to three substituents selected from C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, C.sub.1-4 alkoxy, C.sub.1-4 haloalkoxy, cyano and halo, phenoxy optionally substituted with one to three substituents selected from C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, C.sub.1-4 alkoxy, C.sub.1-4 haloalkoxy, cyano and halo, phenylthio optionally substituted with one to three substituents selected from C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, C.sub.1-4 alkoxy, C.sub.1-4 haloalkoxy, cyano and halo, and phenylsulfinyl optionally substituted with one to three substituents selected from C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, C.sub.1-4 alkoxy, C.sub.1-4 haloalkoxy, cyano and halo; and optionally substituted with one to three substituents selected from C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, halo, C.sub.1-4 alkoxy, hydroxy, phenyl optionally substituted with one to three substituents selected from C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, C.sub.1-4 alkoxy, C.sub.1-4 haloalkoxy, cyano and halo, phenoxy optionally substituted with one to three substituents selected from C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, C.sub.1-4 alkoxy, C.sub.1-4 haloalkoxy, cyano and halo, and phenylthio optionally substituted with one to three substituents selected from C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, C.sub.1-4 alkoxy, C.sub.1-4 haloalkoxy, cyano and halo; --(CHR.sup.1).sub.m --Q.sup.1 (CHR.sup.2).sub.n --, --O--(CHR.sup.1).sub.j --Q.sup.2 -- and --(CHR.sup.1)--O--N.dbd. in which the N.dbd. moiety is attached to the cycloalkene ring; and in which Q.sup.1 is O, S, SO, SO.sub.2, NR.sup.3, CH.dbd.N--O or CO, Q.sup.2 is O, S, SO, SO.sub.2 or NR.sup.3, and R.sup.1, R.sup.2 and R.sup.3 are each hydrogen or C.sub.1 -C.sub.4 alkyl, m and n are each an integer from 0 to 4 and j is an integer from 1 to 4; C.sub.2-4 alkoxyalkyl, C.sub.1-4 alkylthio, hydroxy, halo, cyano or amino; acceptable metabolically cleavable group.
Kawai Akiyoshi
Kawai Makoto
Stevens Rodney W.
Appleman Jolene W.
Davis Brian J.
Geist Gary
Ginsburg Paul H.
Pfizer Inc.
LandOfFree
Aryloxycycloalkenyl and aryloxyiminocycloalkenylhydroxyureas does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryloxycycloalkenyl and aryloxyiminocycloalkenylhydroxyureas, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryloxycycloalkenyl and aryloxyiminocycloalkenylhydroxyureas will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-36705